Ben Reinhardt tackles a question that has long haunted ambitious scientists and engineers: where does the money go when a project is too weird for a university grant and too risky for a venture capitalist? The piece's most striking insight is that the "messy middle" of research funding isn't a void, but a fragmented landscape of non-dilutive grants, patient capital, and high-risk bets that most observers fail to map. For the busy professional trying to understand where the next breakthrough will come from, this breakdown of funding mechanics is essential reading.
The Illusion of "Free" Money
Reinhardt begins by dismantling the romantic notion that non-dilutive funding—money that doesn't require giving up equity—is simply "free." He writes, "Raising non-dilutive funding usually takes significantly more time and effort than the equivalent amount of investment dollars; most funders impose much more process up front and restrictions on how money can be spent." This is a crucial correction to the narrative that philanthropy is the easy path for misfit research. The author argues that while foundations gave $30 billion toward research in 2019, the bureaucratic machinery of these institutions often forces work into traditional boxes.
The core of the argument here is that the structure of philanthropy often contradicts its mission. Reinhardt notes that "the bureaucracy and processes of most foundations make it hard for them to support non-traditional work," as program officers are bound by tight mandates set by boards of trustees. This framing is effective because it shifts the blame from a lack of available capital to the rigidity of the institutions holding it. However, critics might note that the landscape is shifting; the rise of agile, mission-driven foundations suggests the "traditional" model is under pressure to evolve, even if the author treats it as a static barrier.
Foundations typically deploy money through program officers who work within tight bounds set by the board of trustees on a yearly basis.
The Double-Edged Sword of Dilutive Capital
When the piece moves to dilutive funding—where investors expect ownership and financial returns—the analysis becomes more nuanced. Reinhardt warns that professional investors "need companies in their portfolio to show year-over-year growth, which can be at odds with the uncertainty baked into research." This tension is the central conflict for any research-heavy startup. The author points out that while venture capital can fuel innovation, it often does so only during "bubbles" when an area is "hot" enough to ignore the lack of a clear path to profitability.
The commentary here is sharp: Reinhardt suggests that for many misfit projects, seeking dilutive funding is a strategic error. He writes, "Many misfit research projects will never be a good fit for venture capital, so raising dilutive funding can be a trap." This is a vital distinction for founders to understand. The pressure to scale can kill the very research that makes the company unique. Yet, the piece acknowledges exceptions, such as "patient capital" from impact investors who accept longer timelines, like Breakthrough Energy Ventures operating on a 20-year horizon.
The Wild Cards: DAOs and Family Offices
Perhaps the most forward-looking section of the article explores the entities that don't fit neatly into the binary of grants versus venture capital. Reinhardt highlights Decentralized Autonomous Organizations (DAOs) and Family Offices as emerging powerhouses for unconventional research. He explains that "HNWIs [High-Net-Worth Individuals] often fund things quietly and make themselves hard to contact for obvious reasons: everybody would be asking them for money and funding strange things can open people up to reputational risk."
This observation about the hidden economy of research is compelling. It suggests that the future of "misfit" science may not lie in public institutions or public markets, but in the private, opaque decisions of wealthy individuals and decentralized communities. The author notes that family offices, unlike foundations, have multiple mandates including wealth preservation and risk hedging, giving them the flexibility to fund high-risk science that others won't touch. As Reinhardt puts it, "Individuals have the most flexibility of any funders to do unconventional things." This section effectively reorients the reader's search for funding from public applications to private networks.
Many misfit research projects will never be a good fit for venture capital, so raising dilutive funding can be a trap.
Bottom Line
Reinhardt's strongest contribution is the clear-eyed realization that the funding model must match the research timeline; trying to force long-term, high-uncertainty science into a venture capital box is a recipe for failure. The piece's biggest vulnerability is its reliance on the assumption that the current rigidity of foundations and the risk-aversion of traditional VCs will persist, potentially underestimating how quickly institutional norms can shift in response to technological disruption. For anyone looking to fund or conduct research that doesn't fit the mold, the verdict is clear: know your funder's constraints before you pitch your vision.